EFFECT OF FOLIC ACID SUPPLEMENTATION ON HOMOCYSTEINE LEVEL IN POSTMENOPAUSAL WOMEN
AbstractBACKGROUND: Hyperhomocysteinemia is an independent risk factor for atheroscleroticdiseases including Ischaemic heart disease, stroke and peripheral vascular disease. Homocysteine(Hcy) is an intermediate formed during the catabolism of essential sulphur containing amino acidmethionine, increased Hcy is associated with endothelial dysfunctions in healthy human. PlasmaHcy is significantly lower in premenopausal women than young men but after menopause basalhomocysteinemia increases significantly in women approaching those in men. Several studiesshowed that hyperhomocysteinemia to be stronger risk factor for CHD (Coronary Heart Disease)in women than men. It seems likely that altered hormonal status and age related low folate intakeare responsible for this. The present study was designed to evaluate the effect of folic acidsupplements for six months, on Hcy level in postmenopausal women. Methods: Hcy wasestimated by Flourescence Polarization Immunoassay (FPIA). Results: There was a significant(p<0.001) decrease in Hcy level after six months of folic acid supplements. Conclusion: Hcy is anindependent risk factor for atherosclerotic disease, this study favours the view that aftermenopause Hcy level increases significantly and a simple non Toxic and relatively inexpensivevitamin (folic acid) intervention might be useful in primary cardiovascular prevention in this highrisk group because Hcy is a stronger risk factor for CHD in postmenopausal women than men.Keywords: Menopause, Homocysteine, Folic acid.
Moustapha A and Robinson K. Homocysteine: an emerging
age-related cardiovascular risk factor. Geriatrics 1999;
Virdis A, Ghiadoni L, Salvetti G, Versari D, Taddei S and
Salvett A. Hyperhomocysteinaemia: is the novel risk factor in
hypertention. J. Nephrol 2002;15:414–21.
Ceperkovic Z. The role of increased levels of homocysteine
in the development of cardiovascular diseases. Med Preg
Kang SS, Wong PW, Cook HY, Norusis M and Messer JV.
Protein-bound homocysteine. A possible risk factor for
coronary artery disease.J Clin Invest 1998;77:1482–6
Wouters MG, Moorees MT, Van der Mooren MJ, Bloom HJ,
Boers GH, Schellekens LA et al. Plasma homocysteine and
menopausal status. Eur J Invest 1995;25:801–5.
Anker G, Lonning PE, Ueland PM, Refsum H and Lien EA.
Plasma levels of atherogenic amino acid homocysteine in
postmenopausal women with breast cancer treated with
tamoxifen. Int J Cancer 1995;60:365–8.
Stanger O, Semmelrock HJ, Wonisch W, Bos U, Pabst E,
Wascher TC. Effects of folate treatment and homocysteine
lowering on resistance vessel reactivity in atherosclerotic
subjects. J Pharmacol Exp Ther 2002 Oct;303(1):158–62.
Mijatovic V and Van der Mooren MJ. Homocysteine in post
menopausal and the importance of hormone replacement
therapy. Clin Chem Lab Med 2002;39:764–7.
Pines A, Bornstein NM and Shapira I. Menopause and
ischaemic stroke: basic, clinical and epidemiological
considerations. The role of hormone replacement. Hum
Period Update 2002;8:161–8.
Weiss N, Keller C, Hoffmann U and Loscalzo J. Endothelial
dysfynction and atherothrombosis in mild
hyperhomocysteinaemia. Vasc Med 2002;7:227–39.
Tofler GH, D’Agostino RB, Jacques PF, Bostom AG, Wilson
PW, Lipinska I et al. Association between increased
homocysteine levels and impaired fibrinolytic potential:
Potential mechanism for cardiovascular risk. Thromb
Austin RC, Lentz SR and Werstuck GH. Role of hyperhomocysteinemia in endothelial dyafunction and atherothrombotic
disaese. Cell Death Differ. 2004 Jul;11 Suppl 1:s56-64.
Walsh BW, Paul S, Wild RA, Dean RA, Tracy RP, Cox DX
et al. The effects of hormone replacement therapy and
raloxifene on C-reactive protein and homocysteine in healthy
postmenopausal women: a randomized, controlled trial. J
Clin Endocrinol Metab 2000;85:214-8.
J Ayub Med Coll Abbottabad;19(4)
El-Swefy SA, Ali ST, Asker ME and Mohamed HE.
Hyperhomocysteinaemia and cardiovascular risk in female
ovariectomized rats: role of folic acid and hormone
replacement therapy. J Pharm Pharmacol 2002;54:391–7.
Laraqui A, Bennouar N, Meggouh F, Allami A, Kadri NE,
Benkuoka F et al. Homocysteine, lipoprotein (a): risk factors for
coronary heart disease. Ann Biol Clin Paris 2002;60:549–57.
Ridker PM, Manson JE, Buring JE, Shih J, Matias M and
Hennekens CH. Homocysteine and risk of cardiovascular
disease among postmenopausal women. JAMA
Knopp RH. Risk factors for coronary artery disease in
women. Am J Cardiol 2002;89:34–5.
Verhoef P. Hyperhomocysteinemia and risk of vascular
disease in women. Semin Thromb Hemost 2000;26:325–34.
Reiss RP, Azinheira J, Reiss HP, Pina JE, Correia Jm and
Luis AS. The effect of sex and menopause on basal blood
levels of homocysteine and after methionine loading. Rev
Port Cardiol 1999;18:155–9.
Godsland IF, Wynn V, Crook D and Miller NE. Sex, plasma
lipoproteins, and atherosclerosis: prevailing assumptions and
outstanding questions. Am Heart J 1987;114:1467–1503.
Fernandez-Miranda C, De la Calle M, Manuel Bris J, Muelas
M, Gomez P and Diaz-Rubio P. Influence of menopausal
status in homocysteine plasma levels. Med Clin Barc
Wald DS, Law M, Morris JK. The dose response relation
between between serum homocysteine and cardiovascular
disease: implications for treatment and screening. Eur J
Cardiovasc Prev Rehabil 2004 Jun;11(3):250–3.
Araki R, Maruyama C, Igarashi S and Yoshida M. Effect of
short-term folic acid and/or riboflavin supplementation on
serum folate and plasma total homocysteine concentrations in
young Japanese male subjects. Eur J Clin Nutr 2006
Bloom HJ, Boers GH, Van den Elzen JP, Van Roessel JJ,
Trijbels JM and Tangerman A. Difference between
premenopausal women and young men in the transamination
pathway of methionine catabolism and the protection against
vascular disease. Eur J Clin 1988;Invest.18:633–8.
Hak AE, Polderman KH, Westendrop IC, Jakobs C, Hofman
A, Witteman JC et al. Increased plasma homocysteine after
menopause. Atherosclerosis 2000;149:163–8.
Christodoulakos G, Panoulis C, Rizos D, Moustakarias T,
Phocas I and Creatsas G. Homocysteine and folate levels in
postmenopausal women. Maturitas 2001;39:161–7.
Madsen JS, Kristensen SR, Klitgaard NA, Bladbjerg EM,
Abrahamsen B, Stilgren L et al. Effects of long-term
hormone replacement therapy on plasma homocysteine in
post menopausal women: a randomized controlled study. Am
J Obset Gynecol 2002;87:33–9.
Zak A, Zeman M. Consequences of moderate hyperhomocysteinemia in the internal medicine. Cas Lek Cesk
Lonn E, Yusuf S, Arnold MJ, Sheridan P and Pogue J.
Homocysteine lowering with folic acid and B Vitamins in
vascular disease. N England J Med 2006 Apr
Connor JJ., Meurer LN. Should Practice with coronary
disease and high homocysteine take folic acid? J Fam Pract
Neal B., MacMahon S., Ohkubo T., Tonkin A., Wilcken D.
Dose-dependent effects of folic acid on plasma homocysteine
in a randomized trial conducted among 723 individuals with
coronary heart disease. Eur Heart J 2002 Oct;23(19):1509–15.